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Background: Trastuzumab (T) combined with chemotherapy has been recently shown to improve outcome in
HER2-positive breast cancer (BC). The aim of this study was to evaluate the toxic effects of concurrent radiation
therapy (RT) and T administration in the adjuvant setting.
Patients and methods: Data of 146 patients with stages II–III HER2-positive BC were recorded. Median age was
46 years. In all, 32 (23%) and 114 (77%) patients received a weekly and a 3-week T schedule, respectively. A median
dose of 50 Gy was delivered after surgery. Internal mammary chain (IMC) was irradiated in 103 (71%) patients.
Results: Grade >2 dermatitis and esophagitis were noted in 51% and 12%, respectively. According to the Common
Toxicity Criteria v3.0 scale and HERA (HERceptin Adjuvant) trial criteria, respectively, 10% and 6% of the patients had
a grade ‡2 of left ventricular ejection fraction (LVEF) decrease after RT. Multivariate analyses revealed two independent
prognostic factors: weekly T administration (for LVEF decrease) and menopausal status (for dermatitis). Higher level of
T cumulative dose (>1600 mg) was only borderline of statistical significance for acute esophagitis toxicity.
Conclusion: We showed that weekly concurrent T and RT are feasible in daily clinical practice with, however,
a decrease of LVEF. Cardiac volume sparing and patient selections for IMC irradiation are highly recommended.
Longer follow-up is warranted to evaluate late toxic effects.
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introduction
The rate of breast cancers (BCs) overexpressing HER2 is 20%
[1]. Before the targeted treatment era, HER2 BC was associated
with an increasing risk of disease progression and poorer
prognosis [2]. Trastuzumab (T) is a humanized recombinant
mAb that binds with high affinity to the extracellular domain
of the HER2 receptor [2]. Its impact on disease-free survival
(DFS) and overall survival has been shown recently when given
as adjuvant therapy for HER2-positive early BC [3–7].
Nevertheless, the best sequence for adjuvant T administration
regarding timing of chemotherapy (CT) and radiation
therapy (RT) is still unclear.
In the metastatic setting, randomized trials have indicated
a synergistic effect of T and taxane combination leading to
better survival compared with CT alone [8, 9]. The
principal adverse event associated with T therapy among
patients with prior or concurrent exposure to anthracycline
was cardiac dysfunction [10].
In an experimental model of MCF-7 cell lines overexpressing
HER2 and in xenograft tumors, Pietras et al. [11] reported
a significant radiosensibilization of combined T and
radiation exposure compared with T or radiation alone.
The risk of toxicity of combined T and RT on normal tissues
has not yet been evaluated in detail. Thus, we investigated the
risk of cardiac, skin, and esophagus toxic effects following
concurrent administration of adjuvant T and locoregional
radiotherapy in patients with HER2-positive BC.
patients and methods
This study was designed in July 2005. As there was no particular
recommendation at that time for T-timing administration in France,
sequential or concomitant T–radiotherapy was delivered according to each
center’s policy. Nine centers evaluated their patients according to
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a Common Toxicity Criteria (CTC) list. Each local institutional review
board approved the registration.
patients
All registered patients had completely excised ductal or lobular carcinoma
of the breast with HER2 overexpression or proven HER2 amplification. All
patients received T and adjuvant RT.
At the time of this analysis, all patients have completed their treatment
since at least 3 months. Median age was 46 years (range: 23–82 years).
Ninety patients of 146 (62%) were nonmenopausal, and half of the patients
were treated for left BC. The majority of the patients (98%) had grade II or
III tumors, and half of them had nodal involvement (54%), or were
hormone receptor positive (HR+) (53%). Patients’ characteristics are
detailed in Table 1.
treatment modalities
T was started before and after surgery in 71 (49%) and 75 patients (51%),
respectively. In all, 78 (53%) and 68 (47%) patients had total mastectomy
and conservative surgery, respectively. In all cases, T was planned for 1 year,
radiotherapy was delivered concurrently with T. CT consisted of
a sequential combination of anthracyclines and taxanes.
In all, 32 (23%) and 114 (77%) of the 146 patients received a weekly and
a 3-weekly T schedule, respectively. The median dose of T before RT was
1600 mg (range: 0–4312 mg). Endocrine therapy was administered in 74
HR+ patients. It consisted of tamoxifen [with or without luteinizing
hormone-releasing hormone (LH-RH) agonists] and aromatase inhibitors
in 34 (46%) and 40 (54%) patients, respectively.
The median dose delivered to the whole breast or the chest wall was 50
Gy (range: 40–50 Gy) in 25 fractions. A 10- to 16-Gy boost in five to eight
fractions was delivered to the tumor bed in 68 patients using mainly
electron beams (61 of 68, 90%).
Internal mammary chain (IMC) nodes were irradiated in 103 of 146
patients (71%). The median dose was 50 Gy (range: 15–50.4 Gy) in 25
(range: 7–28) fractions delivered mainly by a mixed photon–electron
technique (93 of 103, 90%). Supraclavicular nodes were irradiated in 122 of
146 patients (84%). The median dose was 46 Gy (range: 30–50 Gy) in 23
(range: 10–25) fractions delivered following mixed photon–electron beams,
electrons alone, or using teletherapy unit in 77 (63%), 35 (29%), and 1
(8%) patients, respectively. Treatment modalities are detailed in Table 2.
statistical analyses
Toxicity assessment of the skin and esophagus was implemented according
to the CTC v3.0 scale [12]. Cardiac toxicity was assessed according to the
left ventricular ejection fraction (LVEF) decrease before and after RT
completion. Acute toxicity (grade ‡2) was defined using both CTC v3.0
scale [12] and the HERA trial criteria [6] (decrease in the ejection fraction
of ‡10 points from baseline to LVEF of <50% at any time).
Actuarial rates of toxic effects were calculated using the product-limit
method [13]. The event was grade ‡2 toxicity at different observation times
from the date of RT completion. Differences between groups were assessed
using the log-rank test [14]. Multivariate analyses were implemented using
the logistic regression analysis [15]. A stepwise backward procedure was
used to construct a set of independent predictors of each end point. All
predictors achieving a P value <0.10 were considered and sequentially
removed if the P value in the multiple models was >0.05. All tests were
two-sided. No P value corrections were made for multiple testing.
results
acute toxic effects and outcome
Acute toxic effects are detailed in Table 3. Among 135 patients
who had clinical evaluation during and after the RT period,
66 (51%) developed grade ‡2 dermatitis. Grade ‡2 esophagitis
was observed in 16 of 136 patients (12%). RT was suspended in
three patients for 5–10 days but all of them completed the
initial planned treatment.
LVEF decreased after RT ranged between 0 and 24 points
(median: 6). According to the CTC v3.0 scale and HERA trial
Table 1. Patients’ characteristics (n = 146)
Parameters n %
Age (years)
Median 46 –
Mean (SD) 48 (11) –
Range 23–82 –
Menopausal status
Menopausal 56 38
Nonmenopausal 90 62
Breast side
Left 62 42
Right 79 54
Bilateral 5 4
Type of surgery
TMa 78 53
BCS 68 47
Histology type
Ductal carcinoma 143 98
Lobular carcinoma 3 2
Pathologic tumor size (mm)
Median 21 –
Mean (SD) 25 (17) –
Rangeb 0–80 –
Pathologic tumor classification
pT0b 21 14
pT1 53 36
pT2 53 36
pT3–pT4 19 14
Pathologic nodal statusc
Node negative 67 46
Node positived
1–3 N+ 55 38
‡4 N+ 24 16
Grade
Grade 1 3 2
Grade 2 52 36
Grade 3 91 62
HR status
HR2 68 47
ER+ and/or PR+ 78 53
HER2 status positive in IHC
3+ score 134 92
2+ score 12 8
aFour patients had breast reconstruction.
bTumor size = 0 in 21 patients who had neo-adjuvant chemotherapy +/2
trastuzumab.
cMedian number of nodes = 10 (range: 1–25).
dExtracapsular node involvement (n = 13).
SD, standard deviation; TM, total mastectomy; BCS, breast-conserving
surgery; HR, hormone receptor; ER, estrogen receptor; PR, progesterone
receptors; IHC, immunohistochemistry.
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criteria, 9 of 92 patients (10%) and 6 of 111 patients (6%),
respectively, had a grade ‡2 of LVEF decrease.
After a median follow-up of 16 months (range: 4–30
months), all patients were alive. Five of 146 (3%) developed
distant metastases [brain (n = 2) and liver (n = 3)]. None of
the patients had local or locoregional recurrence or
contralateral BC.
univariate and multivariate analyses
Univariate analyses are shown in Tables 4 and 5. In terms of
skin acute toxicity, 38% of the nonmenopausal patients
developed grade ‡2 dermatitis versus 65% of the menopausal
patients (P = 0.002). There was a trend for statistical
significance between patients younger than 46 years compared
with those 46 years or older (56% versus 40%; P = 0.063). In
patients who received a cumulative dose of T ‡1600 mg and
concurrent RT including IMC, grade ‡2 esophagitis was
higher (17%) than those who received <1600 mg of T (6%)
with border statistical difference (P = 0.05). A higher rate
was also observed after total mastectomy compared with
conservative surgery; however, the limit of statistical
significance was not reached (P = 0.08). In terms of LVEF
decrease after RT, either using CTC v3.0 scale or HERA
criteria, we found a significant impact of menopausal status
(P = 0.0006 and 0.001, respectively), age (P = 0.004 and 0.001,
respectively), and weekly T schedule (P = 0.0018 and 0.005,
respectively).
Table 2. Treatment modalities
Groups n %
Adjuvant chemotherapy
Total duration (months)
Median 3.8
Mean (SD) 4.1 (0.8)
Trastuzumab administration modalities
Schedule
Weekly 32 23
3 weeks 114 77
Cumulative dose of trastuzumab (mg) (n = 137)
<1600 65 47
‡1600 72 53
Endocrine therapy
Type of ET (n = 74)
TAM and/or LH-RHa
antagonists
34 46
AI 40 54
Locoregional RT
Dose (Gy)
Median 50
Mean (SD)/range 48 (2)/40–54
Boost to the tumor bed
Boost 68 53
No boost 78 47
IMC
IMC RT 103 71
No IMC RT 43 29
IMC dose
Median 50
Mean (SD) 48 (4)
Range 15–50.4
SC RT
SC RT 122 84
No SC RT 24 16
SC RT dose
Median 46
Mean (SD)/range 46 (3)/30–50
aLH-RH antagonists administered in 24 of 90 (27%) nonmenopausal patients.
SD, standard deviation; ET, endocrine therapy; TAM, tamoxifen; LH-RH;
luteinizing hormone-releasing hormone; AI, aromatase inhibitors; RT,
radiation therapy; IMC RT, internal mammary chain-radiation therapy; SC,
supraclavicular.
Table 3. Results of toxicity
n %
Skin toxicity (CTC v3.0)
Early dermatitis (during RT; n = 143)
Grade 0 32 22
Grade 1 53 37
Grade 2 50 35
Grade 3 8 6
Skin toxicity at any time (during or following RT; n = 135)
‡Grade 2 66 51
<Grade 2 69 48
Esophagus toxicity (CTC v3.0)
Early esophagitis (during RT) (n = 136)
Grade 0 86 64
Grade 1 32 24
Grade 2 15 11
Grade 3 1 1
Esophagus toxicity at any time (during or after RT; n = 136)
‡Grade 2 16 12
<Grade 2 120 88
RT suspended because of dermatitis or esophagitis
RT suspended during 5–10 days
Yes 3 2
No 88 60
NA 55 38
LVEF decrease after RT
Decrease of LVEF (number of points)
Median 5
Mean (SD) 6 (5)
Range 0–24
Decrease of LVEF
Defined by CTC v3.0 scalea
(n = 92)
9 10
Defined following HERA trial
criteriab (n = 111)
6 5
aCTC v3.0—grade 1: ejection fraction <60%–50%; grade 2: ejection fraction
<50%–40%.
bHERA trial criteria: decrease in LVEF defined as a decrease in the ejection
fraction of ‡10 points from baseline to an LVEF of <50% at any time.
CTC, Common Toxicity Criteria; NA, not available; RT, radiation
therapy; LVEF, left ventricular ejection fraction; SD, standard deviation.
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Multivariate analysis revealed three unfavorable prognostic
factors: weekly T administration (for the risk of LVEF decrease;
P = 0.004 and 0.04, according to HERA and CTC v3.0
criteria, respectively), menopausal status (for grade >2
dermatitis; P = 0.002). The limit of statistical significance
was only borderline (P = 0.05) for the impact of higher T
cumulative dose on esophagitis.
Table 4. Univariate analyses of early cardiac, esophagus, and skin toxic
effects after RT
Parameters Decrease of LVEF
following HERA
trial criteriaa
Decrease of LVEF
‡grade 2 (CTC
v3.0 scale)b
n = 111 % P value n = 112 % P value
Age (years)
>46 6/53 10 0.004 8/59 14 0.001
£46 0/58 0 1/53 2
Menopausal status
Menopausal 6/44 5 0.0006 8/45 18 0.001
Nonmenopausal 0/67 0 1/67 1
Breast side
Left 1/42 2 0.24 2/43 5 0.28
Right 5/69 7 7/69 10
Type of surgery
TM 5/63 8 0.15 6/63 10 0.5
BCS 1/48 2 3/49 6
Neo-adjuvant CT
Administered 2/55 4 0.40 4/56 7 0.72
Not administered 4/56 7 5/56 9
Adjuvant CT
Administered 4/56 7 0.40 5/56 9 0.72
Not administered 2/55 4 4/56 7
Total duration of CT (months)
‡3 3/52 5 0.87 4/56 7 0.60
<3 3/59 6 5/56 9
Type of CT
AT 2/47 4 0.64 3/48 6 0.54
Other combinations 4/64 6 6/64 9
Trastuzumab schedule
Weekly 5/27 19 0.0018 6/28 21 0.005
3 weeks 1/82 1 3/84 3
Endocrine therapy
AI 4/31 13 0.04 5/32 16 0.07
TAM +/2 LH-RH
analogs
2/80 2 4/80 5
Internal mammary chain
RT 4/75 5 0.96 7/76 9 0.49
No RT 2/36 5 2/36 5
Supraclavicular
RT 5/94 5 0.92 8/95 8 0.71
No RT 1/17 6 1/17 6
Cumulative dose of trastuzumab before RT (mg)
<1600 1/47 2 0.12 3/47 6 0.46
‡1600 5/57 10 6/58 10
aHERA trial criteria: decrease in LVEF defined as a decrease in the ejection
fraction of ‡10 points from baseline to LVEF of <50% at any time.
bCTC v3.0—grade 1: ejection fraction <60%–50%; grade 2: ejection fraction
<50%–40%.
LVEF, left ventricular ejection fraction; CTC, Common Toxicity Criteria;
TM; total mastectomy; BCS: breast-conserving surgery; CT: chemotherapy;
AT: anthracyclines and taxanes; AI, aromatase inhibitors; TAM, tamoxifen;
LH-RH, luteinizing hormone-releasing hormone; RT: radiation therapy.
Table 5. Univariate analyses of skin and esophageal toxic effects during
and 3 months following RT
Parameters Skin acute toxicity
grade ‡2 (CTC
v3.0 scale)
Esophagitis
grade ‡2 (CTC
v3.0 scale)
n = 135 % P value n = 136 % P value
Age (years)
>46 24/60 40 0.063 7/61 9 0.33
£46 42/75 56 9/75 15
Menopausal status
Menopausal 34/52 65 0.002 5/50 10 0.62
Nonmenopausal 32/83 38 11/86 13
Breast side
Left 23/55 42 0.17 6/60 10 0.56
Right 43/80 54 10/76 13
Type of surgery
TM 34/70 49 0.93 12/75 16 0.08
CS 32/65 49 4/61 7
Neo-adjuvant CT
Administered 33/67 49 0.93 10/69 14 0.31
Not administered 33/68 49 6/67 9
Adjuvant CT
Administered 33/67 49 0.93 6/67 9 0.31
Not administered 33/68 49 10/69 14
Total duration of CT (months)
‡3 30/63 48 0.78 8/59 14 0.57
<3 36/72 50 8/77 10
Type of CT
AT 26/58 44 0.41 8/63 13 0.75
Other combinations 40/77 52 8/73 11
Trastuzumab schedule
Weekly 14/29 48 0.86 2/30 7 0.26
Every 3 weeks 51/102 50 14/102 13
Trastuzumab–RT combination
Weekly 13/28 46 0.37 2/31 6 0.14
3WT-RT 42/90 46 14/96 14
3WT after RT completion 11/17 64 0/9 0
Endocrine therapy
AI 19/34 56 0.34 4/36 11 0.88
TAM +/2 LH-RH
analogs
47/101 46 12/100 12
Internal mammary chain
RT 46/95 48 0.86 13/93 14 0.21
No RT 20/40 50 3/43 7
Supraclavicular
RT 56/113 49 0.72 15/113 13 0.17
No RT 10/22 45 1/23 4
Cumulative dose of trastuzumab before RT (mg)
<1600 28/59 47 0.89 4/64 6 0.05
‡1600 31/67 46 12/71 17
CTC, Common Toxicity Criteria; TM, total mastectomy; CS, conservative
surgery; CT, chemotherapy; AT, anthracyclines and taxanes; WT, weeks-
trastuzumab; RT, radiation therapy; AI, aromatase inhibitors; TAM,
tamoxifen; LH-RH; luteinizing hormone-releasing hormone.
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discussion
This study was undertaken to examine whether there was an
association between the use of T concurrently with RT for
HER2-overexpressing BC patients in the adjuvant setting.
In the North American [3] and HERA [4, 5] phase III trials,
using 1-year T schedule, the absolute DFS benefit was 12% at 3
years and 18% at 4 years, respectively. The HERA trial has
recently reported a benefit of 2.7% in overall survival in
patients treated by T in adjuvant setting [5]. In FinHer trial [6]
with only a 9-week administration of T, the DFS benefit was
42% at 38 months. This increase of survival was associated with
acceptable toxicity in particular cardiac toxicity, which was
mostly reversible. Conversely, the best sequence regarding
timing of RT could not be determined from these trials.
Thus, it remains unclear whether concurrent administration
of T and RT could alter normal cardiac, skin, and oesophageal
tissues. Even if these acute reactions could be reversible, their
impact on late sequelae is still not predictable.
Pietras et al. [11] have indicated a synergistic effect of
T and ionizing radiation in experimental models. They showed
in an in vitro model of MCF-7 HER2-positive cells a significant
inhibition of DNA repair after concomitant X-ray and T exposure
compared with T or irradiation alone. Their results were
confirmed in vivo in xenografts usingMCF-7HER2-positive cells.
In humans, the synergistic antitumor effect of T in
combination with RT has been investigated recently in
HER2-positive high-risk (n = 15) and chemoresistant (n = 7)
BC [16]. The schedule consisted of hypofractionated and
accelerated irradiation combined to 4 mg/kg every 2 weeks of
T. CT consisted of doxorubicin (25 mg/m2 every 2 weeks) or
docetaxel (40 mg/m2 every 2 weeks). With the addition of
a cytoprotectant (Amifostine, Ethyol; Schering Plough
Laboratories), this schedule was well tolerated. After 3–26
months of follow-up there was no recurrence. A complete
response was observed in 5 of 7 patients with locally
advanced or chemoresistant disease.
The concern of our study was the potential synergistic
effect of concurrent T–RT on normal tissues involved in the
radiation field.
The overall incidence of grade 2 or more acute skin reactions
was 51%. The follow-up in our study remains short and render
impossible to predict the outcome of skin reactions and
particularly the probability of late breast fibrosis. In the
Dana Farber experience [17], using a weekly concurrent T (2
mg/m2; n = 21) or a 3-weekly schedule (6 mg/m2; n = 5), the
grades 2 and 3 skin toxicity rates were 48% and 8%,
respectively. The median follow-up period of 26 months is
still short to allow relevant evaluation of late skin sequelea.
In this series two patients (8%) developed interstitial
pneumonitis. In our experience, among the patients who
received supraclavicular RT (84%), none developed lung
toxicity clinically after a 16-month median follow-up period.
In addition, it is important to point out that none of these
preliminary reports have taken into account age and the
breast volume variation for skin toxicity evaluation.
Halyard et al. [18] reported a retrospective comparison of
irradiated (n = 908) versus nonirradiated patients (n = 308)
from the North Central Cancer Treatment Group phase III
trial. After an 18-month median follow-up, concurrent T and
RT administration did not increase skin toxicity (P = 0.78),
interstitial pneumonitis (P = 0.78), dyspnea (P = 0.87), or
esophagitis (P = 0.26). The results regarding esophagus and
cardiac toxic effects have to be interpreted cautiously as the
authors reported that among the 41 patients (3%) who had
IMC irradiation the heart was shielded using blocks. In such
cases, the pertinence of esophagus and cardiac toxicity
analysis has to be questioned regarding the very low doses
delivered to these tissues.
In the current report and according to the widely known
impact of cumulative dose of anthracyclines on cardiac toxicity,
we analyzed the influence of cumulative dose of T on acute
toxic effects. In contrast to the anthracyclines data on heart
and skin radiosensibilization, cumulative dose of T did not
modify radiation-induced acute toxic effects of these tissues.
Among 71% of the patients who received a median dose of 50
Gy to the IMC, the rate of grade 2 or more esophagitis was
12% during RT but remained reversible in the majority of
the cases (11%) at 3 months after treatment. This has to be
interpreted cautiously as there are no available data in the
literature supporting this finding for the moment. In addition,
the limit of statistical significance was not reached in the
multivariate analysis for T cumulative dose impact on
esophagitis (Table 6). Further studies and long-term follow-up
are warranted to evaluate late sequelea. In the meta-analysis,
the risk of secondary esophagus malignancy after BC
treatment before T era was significantly increased by RT
(relative risk = 2.06; P = 0.05) [19].
There are two options to reduce the risk of radiation-
induced toxicity of the mediastinal organs. The first option may
consist in a high selection of patients who will really benefit
from IMC irradiation, such as patients having total
mastectomy and significant axillary node involvement (‡4
nodes) [20]. In a comparison between IMC irradiation
practice in Europe and in the United States, Taghian et al.
[21] reported a significant difference between the French and
Table 6. Multivariate analyses
Factors Cardiac toxicity evaluation by
LVEF decrease
LVEF decrease:
HERA trial
criteriaa
‡Grade 2 decrease
of LVEF (CTC
v3.0 scale)b
Weekly trastuzumab
administration
0.004 0.04
Esophagitis grade ‡2 (CTC v3.0 scale)
Cumulative dose of
trastuzumab before RT
0.05
Dermatitis grade ‡2 (CTC v3.0 scale)
Postmenopausal status 0.002
aHERA trial criteria: decrease in LVEF defined as a decrease in the ejection
fraction of ‡10 points from baseline to LVEF of <50% at any time.
bCTC v3.0—grade 1: ejection fraction <60%–50%; grade 2: ejection fraction
<50%–40%.
LVEF, left ventricular ejection fraction; CTC, Common Toxicity Criteria;
RT, radiation therapy.
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American practice for both subgroups of patients who had
total mastectomy for intermediate-risk (1–3 nodes; 59% versus
15%) or high-risk (‡4 nodes; 64% versus 24%) BC. This
difference in practice should be taken into account for
interpreting results in future studies involving patients
receiving T and RT.
The second option may consist in the use of intensity-
modulated radiation therapy (IMRT) and gating, which
could allow a highly conformal dose distribution to the
breast (or chest wall) and elective nodes. In the William
Beaumont Hospital experience on 25 patients, the mean cardiac
volume receiving 30 Gy was decreased from 2.6% to 0.6% using
IMRT and gating compared with other techniques. In this
series, the cardiac volume was totally excluded from the
irradiation field in 15 of 25 patients [22]. Furthermore,
another report from the same group has recently indicated
a significant dose reduction via active breathing control during
irradiation for left-sided BC. This was demonstrated using
image fusion from magnetic resonance imaging and
computed tomography scans [23].
Even if no difference in terms of cardiac toxicity was
observed between patients treated for left or right side [24],
irradiated heart volume, previous cumulative dose of
anthracyclines, and T administration are highly suspected to be
involved in the cardiac injury. In addition, it is impossible to
predict whether the reversible decrease of LVEF during T
therapy will impact the late cardiac toxicity in the context-
additive effect of anthracyclines and RT. In the metastatic
setting, a recent report from MD Anderson [25] showed that
the two main prognostic factors for long-term cardiac
tolerability of T were baseline LVEF and time from last
anthracycline administration. In our study, the analyses took
into account the last LVEF value measured before RT as the
reference value. This baseline value was compared with the
lowest value observed at any time of follow-up following RT.
The recent retrospective data analysis of the INTERGROUP
randomized trial [18] did not show any difference according to
the breast side following T and RT. However, the number of
patients who received an IMC RT was low and the follow-up in
this report is still too short to conclude. In a recent report with
longer follow-up after RT alone, Harris et al. [26] reported an
increased cumulative hazard risk of cardiac death in patients
treated for right BC (2.9% at 15 years and 3.6% at 20 years)
compared with the left side (4.4% at 15 years and 6.4% at 20
years). In addition, myocardial infarction rate was significantly
higher in left-side BC patients (15% versus 5%; P = 0.006). In
another recent report, the risk of myocardial infraction
following RT for BC was related to anatomic sites of RT, such
as left breast, anterior left breast boost field, and anterior IMC
field [27]. Indeed, when IMC RT is delivered using only
anterior beam’s photons, the cardiac dose may increase
significantly which can lead to an increased risk of toxicity.
In the present study, the decrease of LVEF according to
HERA and CTC v3.0 criteria have evaluated only acute
cardiac toxicity after a 16-month median follow-up.
Multivariate analysis using both criteria showed that weekly
T schedule was the only unfavorable factor for LVEF decrease.
In our study, 23% and 77% of the patients had weekly and
a 3-week schedule, respectively. The timing and extent of
LVEF reduction after RT alone, however, have to be discussed.
Following left breast RT alone or combined to doxorubicin, the
cardiac perfusion defects detected using single-photon emission
computed tomography are not associated with changes in
regional wall motion or LVEF. To date, there is no report on
evaluating this issue after combined T–RT [28, 29].
Suspending T during RT may not be useful to prevent
cardiac toxicity. Indeed, in practice, such suspension may be
useless because of the half-life of T (4–6 weeks). Besides,
there is a pharmacological similarity between daily and
3-weekly administration of T [30]. In HER2-overexpressing
BC, however, the impact of late outset and/or suspension of
T for 5–7 weeks of irradiation is still unknown. In the case
of concomitant administration of T and RT, the issue lies in
the potential interaction between T set on cardiac tissue
structures and ionizing radiation. Whereas for anthracyclines
and ionizing radiation the physiopathology is on the basis
of the production of free radicals, cell events are less known
for T. Indeed, one limit of preclinical studies is that the
antibody’s humanized variable part is unable to recognize
and thus bind to HER2 receptor in nonsyngeneic animal
models. Moreover, in humans, HER2 expression on
myocardiac cells is low. On myocardiac cells, however, we
noticed HER2/HER4 heterodimers showing the dimerization
of HER receptors as well as the involvement of mitogen-
activated protein kinase/extracellular signal-regulated kinase
and AKT pathways [31, 32]. Such pathways may also be
involved in explaining doxorubicin/T-induced additive toxicity
on myocardiac cells. The doxorubicin-induced apoptotic
phenomena might increase with the addition of T,
inhibiting AKT and extracellular signal-regulated kinase
signal transduction [33]. In addition, interaction between
ionizing radiation and these pathways is known.
conclusion
To our knowledge this is the first study evaluating acute toxicity
of concurrent administration of T and RT. We found that
weekly concurrent T and RT decreased LVEF. The acute skin
and esophagus toxic effects have been resolved at 3 months
following RT. Longer follow-up is warranted to evaluate
whether acute reversible reactions could be predictors of
significant sequelea, in particular cardiac late toxicity in the
setting of anthracycline administration and aromatase
inhibitors era.
At the moment, it is recommended to balance the role of
each therapeutic agent and their potential toxic effects when
used concurrently. It is important to spare the maximum
of heart volume during RT and select the patients who will
really benefit from IMC irradiation.
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